References
- Huynh-Ba K. Handbook of stability testing in pharmaceutical development. New York (NY): Springer Science Business Media; 2008
- Q1A (R2) ICH Harmonized tripartite guideline, stability testing of new drug substances and products; 2003. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002651.pdf [last accessed May 2013]
- Guideline on stability testing: stability testing of existing active substances and related finished products. The European medicines Agency; 2004. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003466.pdf [last accessed May 2013]
- Eli Lilly®Brand council I. Available from: http://www.furiousseasons.com/zyprexa%20documents/ZY200370406.pdf [last accessed Feb 2013]
- Sekhar CBVVN, Kumar RN, Chakravarthy A, Mukkanti K. Novel synthetic approaches for the synthesis of antipsychotic drug olanzapine. Int J Pharm Biol Sci 2011;2:426–32
- Thatipalli P, Kumar R, Bulusu C, et al. Synthesis and characterisation of impurities of an anti-psychotic drug substance, olanzapine. ARKIVOC 2008;xi:195–201
- Hiriyanna SG, Basavaiah K, Goud PSK, et al. Identification and characterization of olanzapine degradation products under oxidative stress conditions. Acta Chromatogr 2008;20:81–93
- Cui D, Li Y, Lian M, et al. Development of a simple and stability indicating RP-HPLC method for determining olanzapine and related impurities generated in the preparative process. Analyst 2011;136:3149–56
- Rao RN, Raju AN, Narsimha R, Babu GR. Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS, J Sep Sci 2008;31:107–18
- Krishnaiah CH, Murphy MV, Kumar R, Mukkanti K. Development of a stability indicating UPLC method for determining olanzapine and its associated degradation products present in active pharmaceutical ingredients and pharmaceutical dosage forms. J Pharm Biomed Anal 2011;54:667–73
- Baertschi SW, Brunner H, Bunnell AC, et al. Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations. J Pharm Sci 2008;97:883–92
- Rao PS, Ray UK, Hiriyanna SG, et al. Identification of oxidative degradation impurities of olanzapine drug substance as well as drug product. J Pharm Biomed Anal 2011;56:413–18
- Peres-Filho MJ, Gaeti MPN, de Oliveira SR, et al. Thermoanalytical investigation of olanzapine compatibility with excipients used in solid oral dosage forms. J Therm Anal Calorim 2011;104:255–60
- European Pharmacopoeia Ed 7.3. Strasbourg, France: Council of Europe; 2012
- United States Pharmacopoeia, 34 NF-29. Olanzapine, US Pharmacopoe Convention, Rockville, MD, USA. 2011:3708–11
- Reutzel-Edens SM, Bush JK, Magee PA, et al. Anhydrates and hydrates of olanzapine: crystallization, solid-state characterization, and structural relationship. Cryst Growth Des 2003;3:897–907
- Airaksinen S, Karjalainen M, Shevchenko A, et al. Role of water in the physical stability of solid dosage form formulations. J Pharm Sci 2005;94:2147–65
- Jain R, Railkar AS, Malick AW, et al. Stability of a hydrophobic drug in presence of hydrous and anhydrous lactose. Eur J Pharm Biopharm 1998;46:177–82
- Perrin CL, Nuiiez O. Absence of stereoelectronic control in hydrolysis of cyclic amidines. J Am Chem Soc 1986;108:5997–6003
- Q3B (R2). ICH harmonized tripartite guideline: impurities in new drug products; 2006. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002676.pdf [last accessed May 2013]
- Guidance for Industry, ANDAs: impurities in drug products. FDA Center for Drug Evaluation and Research; 2006. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072861.pdf [last accessed May 2013]
- Baertschi SW. Pharmaceutical stress testing: predicting drug degradation. USA: Taylor and Francis Group; 2005